[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 52, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 55, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 925331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 56, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 820594, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 45, "title": "CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 573362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient Advocacy & External Affairs Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.465, "open": 2.22, "dayLow": 1.83, "dayHigh": 2.25, "regularMarketPreviousClose": 2.465, "regularMarketOpen": 2.22, "regularMarketDayLow": 1.83, "regularMarketDayHigh": 2.25, "beta": 0.472, "forwardPE": -4.3404255, "volume": 10093152, "regularMarketVolume": 10093152, "averageVolume": 2324859, "averageVolume10days": 4606320, "averageDailyVolume10Day": 4606320, "bid": 2.03, "ask": 2.06, "bidSize": 1500, "askSize": 1400, "marketCap": 381516704, "fiftyTwoWeekLow": 0.582, "fiftyTwoWeekHigh": 4.32, "priceToSalesTrailing12Months": 26.950884, "fiftyDayAverage": 2.9536, "twoHundredDayAverage": 2.39165, "currency": "USD", "enterpriseValue": 318920288, "floatShares": 105874786, "sharesOutstanding": 187018000, "sharesShort": 16121850, "sharesShortPriorMonth": 16908440, "sharesShortPreviousMonthDate": 1714435200, "dateShortInterest": 1717113600, "sharesPercentSharesOut": 0.0862, "heldPercentInsiders": 0.18545, "heldPercentInstitutions": 0.75202006, "shortRatio": 9.68, "shortPercentOfFloat": 0.1173, "impliedSharesOutstanding": 187018000, "bookValue": 0.288, "priceToBook": 7.0833335, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -118005000, "trailingEps": -0.78, "forwardEps": -0.47, "enterpriseToRevenue": 22.529, "enterpriseToEbitda": -4.1, "52WeekChange": 2.0676692, "SandP52WeekChange": 0.24598539, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TSHA", "underlyingSymbol": "TSHA", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "firstTradeDateEpochUtc": 1600954200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fa02d192-bc05-33bd-8c2b-2973d0bcc5d6", "messageBoardId": "finmb_665948579", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.04, "targetHighPrice": 9.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.95, "targetMedianPrice": 7.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 123980000, "totalCashPerShare": 0.663, "ebitda": -77780000, "totalDebt": 61383000, "quickRatio": 3.209, "currentRatio": 3.38, "totalRevenue": 14156000, "debtToEquity": 113.991, "revenuePerShare": 0.09, "returnOnAssets": -0.38858002, "returnOnEquity": -6.06694, "freeCashflow": -57143752, "operatingCashflow": -72631000, "revenueGrowth": -0.275, "grossMargins": 1.0, "operatingMargins": -7.13281, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-27"}]